1994•PubMedRequires access

[Glucose tolerance test and insulin secretion in patients with essential hypertension. Effect of enalapril].

Neves Fde A, Nereu Francisco Mezzomo, N E Kohlmann, O Kohlmann Júnior, Maria Teresa Zanella, Artur Beltrame Ribeiro

Open publisher page 0 citations

Abstract

PURPOSE: To investigate the effects of enalapril upon glucose and insulin metabolism in patients with essential hypertension. METHODS: After 4 weeks of washout and 2 weeks of placebo therapy, 10 hypertensive patients were treated with enalapril for 12-14 weeks. Intravenous glucose tolerance test (IVGTT) during 182 minutes was performed before and after treatment. Venous blood samples were drawn for glucose and insulin determinations. RESULTS: Enalapril caused a significant fall on systolic (-19 +/- 3 mmHg) and diastolic (-10 +/- 2 mmHg) blood pressure. During IVGTT, enalapril induced a small decrease in the area under the curve of glucose (placebo 18,966 +/- 732.6 mg/dl.min and enalapril 17,575 +/- 916.1 mg/dl.min) associated with a small increase in the area under the curve of insulin (placebo 3,155 +/- 446.99 mU/ml.min and enalapril 3.577 +/- 393.92 mU/ml.min). A small rise in the disappearance rate of glucose (Kg) was also observed following enalapril (placebo 2.09 +/- 0.33 and enalapril 2.56 +/- 0.53). The insulin responsiveness to glucose increased significantly from 0.16 +/- 0.020 during placebo to 0.21 +/- 0.023 during enalapril. The insulin sensitivity remained unchanged (placebo 1.97 +/- 0.24 and enalapril 1.83 +/- 0.21). CONCLUSION: In hypertensive patients, the treatment with enalapril induced a small increase (not significant) in glucose tolerance caused by a significant rise in insulin responsiveness to glucose since no modification in insulin sensitivity was observed.

About this research paper

What this paper is about

PURPOSE: To investigate the effects of enalapril upon glucose and insulin metabolism in patients with essential hypertension. METHODS: After 4 weeks of washout and 2 weeks of placebo therapy, 10 hypertensive patients were treated with enalapril for 12-14 weeks. Intravenous glucose tolerance test (IVGTT) during 182 minutes was performed before and after treatment. Venous blood samples were drawn for glucose and insulin determinations. RESULTS: Enalapril caused a significant fall on systolic (-19 +/- 3 mmHg) and diastolic (-10 +/- 2 mmHg) blood pressure. During IVGTT, enalapril induced a small decrease in the area under the curve of glucose (placebo 18,966 +/- 732.6 mg/dl.min and enalapril 17,575 +/- 916.1 mg/dl.min) associated with a small increase in the area under the curve of insulin (placebo 3,155 +/- 446.99 mU/ml.min and enalapril 3.577 +/- 393.92 mU/ml.min). A small rise in the disappearance rate of glucose (Kg) was also observed following enalapril (placebo 2.09 +/- 0.33 and enalapril 2.56 +/- 0.53). The insulin responsiveness to glucose increased significantly from 0.16 +/- 0.020 during placebo to 0.21 +/- 0.023 during enalapril. The insulin sensitivity remained unchanged (placebo 1.97 +/- 0.24 and enalapril 1.83 +/- 0.21). CONCLUSION: In hypertensive patients, the treatment with enalapril induced a small increase (not significant) in glucose tolerance caused by a significant rise in insulin responsiveness to glucose since no modification in insulin sensitivity was observed.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

PURPOSE: To investigate the effects of enalapril upon glucose and insulin metabolism in patients with essential hypertension. METHODS: After 4 weeks of washout and 2 weeks of placebo therapy, 10 hypertensive patients were treated with enalapril for 12-14 weeks. Intravenous glucose tolerance test (IVGTT) during 182 minutes was performed before and after treatment. Venous blood samples were drawn for glucose and insulin determinations. RESULTS: Enalapril caused a significant fall on systolic (-19 +/- 3 mmHg) and diastolic (-10 +/- 2 mmHg) blood pressure. During IVGTT, enalapril induced a small decrease in the area under the curve of glucose (placebo 18,966 +/- 732.6 mg/dl.min and enalapril 17,575 +/- 916.1 mg/dl.min) associated with a small increase in the area under the curve of insulin (placebo 3,155 +/- 446.99 mU/ml.min and enalapril 3.577 +/- 393.92 mU/ml.min). A small rise in the disappearance rate of glucose (Kg) was also observed following enalapril (placebo 2.09 +/- 0.33 and enalapril 2.56 +/- 0.53). The insulin responsiveness to glucose increased significantly from 0.16 +/- 0.020 during placebo to 0.21 +/- 0.023 during enalapril. The insulin sensitivity remained unchanged (placebo 1.97 +/- 0.24 and enalapril 1.83 +/- 0.21). CONCLUSION: In hypertensive patients, the treatment with enalapril induced a small increase (not significant) in glucose tolerance caused by a significant rise in insulin responsiveness to glucose since no modification in insulin sensitivity was observed.

Key concepts: Enalapril, Medicine, Internal medicine, Endocrinology, Insulin, Placebo, Essential hypertension, Blood pressure

Related papers

Back to paper searchBrowse research topicsOriginal source
[Glucose tolerance test and insulin secretion in patients with essential hypertension. Effect of enalapril]. — Research Paper | ScholarLens